Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development
Jan. 10, 2022—Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.
Jan. 5, 2022—A folic acid-like drug changed a DNA process within brain tumors of glioblastoma patients, according to results from a phase 1 clinical trial.
Dec. 16, 2021—Vanderbilt research is blazing a trail for the application of game theory to genomic and health data reidentification risk.
Sep. 30, 2021—Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA.
Vanderbilt experts discuss potential of universal genetic database to balance privacy, law enforcement concerns
Jan. 3, 2019—The pivotal role that long distance familial genetic searches played in the apprehension of the notorious Golden State Killer — and as a tool in dozens more cases since — has led experts from Vanderbilt University and Vanderbilt University Medical Center to make a provocative proposal about how investigative use of DNA should be regulated.